JP2019014758A5 - - Google Patents

Download PDF

Info

Publication number
JP2019014758A5
JP2019014758A5 JP2018206547A JP2018206547A JP2019014758A5 JP 2019014758 A5 JP2019014758 A5 JP 2019014758A5 JP 2018206547 A JP2018206547 A JP 2018206547A JP 2018206547 A JP2018206547 A JP 2018206547A JP 2019014758 A5 JP2019014758 A5 JP 2019014758A5
Authority
JP
Japan
Prior art keywords
composition
optionally substituted
cancer
dutpase
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018206547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019014758A (ja
JP6660993B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019014758A publication Critical patent/JP2019014758A/ja
Publication of JP2019014758A5 publication Critical patent/JP2019014758A5/ja
Application granted granted Critical
Publication of JP6660993B2 publication Critical patent/JP6660993B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018206547A 2013-01-07 2018-11-01 デオキシウリジントリホスファターゼ阻害剤 Active JP6660993B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361749791P 2013-01-07 2013-01-07
US61/749,791 2013-01-07
US201361874643P 2013-09-06 2013-09-06
US61/874,643 2013-09-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015551794A Division JP6450323B2 (ja) 2013-01-07 2014-01-03 デオキシウリジントリホスファターゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2019014758A JP2019014758A (ja) 2019-01-31
JP2019014758A5 true JP2019014758A5 (enExample) 2019-05-09
JP6660993B2 JP6660993B2 (ja) 2020-03-11

Family

ID=50030487

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015551794A Active JP6450323B2 (ja) 2013-01-07 2014-01-03 デオキシウリジントリホスファターゼ阻害剤
JP2018206547A Active JP6660993B2 (ja) 2013-01-07 2018-11-01 デオキシウリジントリホスファターゼ阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015551794A Active JP6450323B2 (ja) 2013-01-07 2014-01-03 デオキシウリジントリホスファターゼ阻害剤

Country Status (7)

Country Link
US (3) US9809571B2 (enExample)
EP (1) EP2941423B1 (enExample)
JP (2) JP6450323B2 (enExample)
CN (1) CN105189478B (enExample)
CA (1) CA2914178C (enExample)
IL (1) IL239827B (enExample)
WO (1) WO2014107622A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6450323B2 (ja) * 2013-01-07 2019-01-09 ユニバーシティ オブ サザン カリフォルニア デオキシウリジントリホスファターゼ阻害剤
CA2935717C (en) 2014-01-03 2022-06-21 University Of Southern California Uracil isostere and pharmaceutical compositions thereof useful as deoxyuridine triphosphatase inhibitors
WO2017006270A1 (en) * 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2017006283A1 (en) 2015-07-08 2017-01-12 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
US10570100B2 (en) * 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
EP3319939B1 (en) 2015-07-08 2024-11-27 CV6 Therapeutics (NI) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
CN109153644B (zh) 2016-03-16 2022-10-21 H·李·莫菲特癌症中心研究有限公司 用以增强效应t细胞功能的针对cereblon的小分子
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
WO2018098204A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
US10829457B2 (en) 2016-11-23 2020-11-10 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098206A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098207A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
WO2018128720A1 (en) 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
HUE057710T2 (hu) 2017-01-23 2022-05-28 Cadent Therapeutics Inc Káliumcsatorna modulátorok
US11730726B2 (en) 2018-07-11 2023-08-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dimeric immuno-modulatory compounds against cereblon-based mechanisms
JP2022508945A (ja) 2018-10-22 2022-01-19 カデント セラピューティクス,インコーポレーテッド カリウムチャネルモジュレーターの結晶形態
CA3185648A1 (en) 2020-06-26 2021-12-30 Cv6 Therapeutics (Ni) Limited Combination therapy with deoxyuridine triphosphatase inhibitors
WO2022197978A1 (en) * 2021-03-17 2022-09-22 President And Fellows Of Harvard College Compositions and methods for modulating mitochondrial function and biogenesis

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4829785B1 (enExample) 1970-03-26 1973-09-13
BE787766A (fr) * 1971-08-21 1973-02-19 Merck Patent Gmbh Imides d'acide glutarique et leur procede de preparation
US4063019A (en) 1976-03-30 1977-12-13 E. R. Squibb & Sons, Inc. [[[(2,4-Dioxo-1-imidazolidinyl)amino]carbonyl]amino]-acetylcephalosporin derivatives
US4304715A (en) 1979-06-08 1981-12-08 Derek Hudson Enkephalin analogues
DE3027596A1 (de) 1980-07-21 1982-02-18 Bayer Ag, 5090 Leverkusen Triazolidin-3,5-dion-oxyalkylverbindungen und verfahren zu ihrer herstellung
JPS5839672A (ja) 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd ウラシル誘導体
JPS60243017A (ja) 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
JPH0674251B2 (ja) 1986-02-07 1994-09-21 全薬工業株式▲会▼社 ビス−ジオキソピペラジン誘導体
JPS63101361A (ja) * 1986-09-08 1988-05-06 ブリティッシュ・テクノロジー・グループ・リミテッド ジオキソピペリジン誘導体を含有する不安解消組成物
FR2644786B1 (fr) 1989-03-21 1993-12-31 Adir Cie Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5599796A (en) 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
EP0793673A1 (en) 1994-11-24 1997-09-10 Takeda Chemical Industries, Ltd. Alpha-ketoamide derivatives as cathepsin l inhibitor
US5962246A (en) 1996-03-29 1999-10-05 The University Of Medicine And Dentistry Of New Jersey dUTPase, its isoforms, and diagnostic and other uses
JPH09286786A (ja) 1996-04-18 1997-11-04 Nippon Paper Ind Co Ltd ピリミジン誘導体及びその抗腫瘍剤としての用途
DE19756212A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
JP4524039B2 (ja) 1997-12-18 2010-08-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Srcファミリーsh2ドメインインヒビターとしてのピリドン
WO2000059874A1 (en) 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
DE10002509A1 (de) * 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
BR0208105A (pt) 2001-03-15 2004-03-09 Astrazeneca Ab Inibidores de metaloproteinase
JP2002284686A (ja) 2001-03-28 2002-10-03 Sankyo Co Ltd スルホンアミド化合物を含有する医薬組成物
EP1385831A2 (en) 2001-04-11 2004-02-04 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
WO2004009559A2 (en) 2002-07-18 2004-01-29 Queen's University At Kingston Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
EP1534696A4 (en) 2002-07-25 2010-04-07 Merck Sharp & Dohme THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDO MINIIDES
GB0221246D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0400290D0 (en) 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
CN101141960A (zh) 2005-01-25 2008-03-12 细胞基因公司 使用4-氨基-2-(3-甲基-2,6-二氧代哌啶-3-基)-异吲哚-1,3-二酮的方法和组合物
WO2006135763A2 (en) 2005-06-09 2006-12-21 The Johns Hopkins University Inhibitors of dna repair enzymes and methods of use thereof
NZ573793A (en) 2006-07-24 2012-01-12 Korea Res Inst Chem Tech Hiv reverse transcriptase inhibitors
EP1939186A1 (en) 2006-12-22 2008-07-02 Sulfidris S.r.l. 5-Fluorouracil derivatives and their use for the treatment of cancer
AR069637A1 (es) 2007-12-10 2010-02-10 Novartis Ag Derivados de pirazinas
WO2009147843A1 (ja) 2008-06-03 2009-12-10 大鵬薬品工業株式会社 ヒトデオキシウリジントリホスファターゼ阻害活性を有する新規ウラシル化合物又はその塩
US20110212467A1 (en) 2008-08-27 2011-09-01 University Of Southern California INHIBITORS OF dUTPase
JP2011231015A (ja) * 2008-08-29 2011-11-17 Taiho Yakuhin Kogyo Kk 含窒素複素環を有する新規ウラシル化合物又はその塩
CN102333788A (zh) 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
CN102458393B (zh) 2009-06-25 2014-08-20 生物验证系统股份公司 治疗肺结核的组合物
JP2013032293A (ja) * 2009-11-30 2013-02-14 Taiho Yakuhin Kogyo Kk ヒトdUTPase阻害活性を有する5−フルオロウラシル化合物又はその塩
AU2010323454B2 (en) 2009-11-30 2014-05-08 Taiho Pharmaceutical Co., Ltd. Anti-tumor effect potentiator
JP2013047189A (ja) 2009-12-25 2013-03-07 Kyorin Pharmaceutical Co Ltd 新規パラバン酸誘導体及びそれらを有効成分とする医薬
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
EP2734517B1 (en) 2011-07-18 2017-08-30 Merck Patent GmbH Benzamides
US9212147B2 (en) 2011-11-15 2015-12-15 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
JP6450323B2 (ja) 2013-01-07 2019-01-09 ユニバーシティ オブ サザン カリフォルニア デオキシウリジントリホスファターゼ阻害剤
CA2935717C (en) 2014-01-03 2022-06-21 University Of Southern California Uracil isostere and pharmaceutical compositions thereof useful as deoxyuridine triphosphatase inhibitors
WO2015142001A2 (ko) 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
JP6364546B2 (ja) 2015-04-30 2018-07-25 大鵬薬品工業株式会社 抗腫瘍剤の副作用軽減剤
JP6479970B2 (ja) 2015-05-01 2019-03-06 大鵬薬品工業株式会社 ウラシル化合物の新規結晶
WO2017006283A1 (en) 2015-07-08 2017-01-12 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
EP3319939B1 (en) 2015-07-08 2024-11-27 CV6 Therapeutics (NI) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
WO2018098206A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
WO2018098207A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098204A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
US10829457B2 (en) 2016-11-23 2020-11-10 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018128720A1 (en) 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Uracil containing compounds

Similar Documents

Publication Publication Date Title
JP2019014758A5 (enExample)
US10179787B2 (en) Chemokine receptor modulators and uses thereof
SA521431048B1 (ar) مركبات بيروليدين
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
JP2017502967A5 (enExample)
JP2019517487A5 (enExample)
JP2016505621A5 (enExample)
JP2016536286A5 (enExample)
JP2011509949A5 (enExample)
JP2013502430A5 (enExample)
MX2023009857A (es) Inhibidores de la glucogeno sintasa 1 (gys1) y metodos de uso de los mismos.
JP2017523997A5 (enExample)
PH12021552482A1 (en) Compounds targeting prmt5
JP2017537882A5 (enExample)
RU2014153920A (ru) Дигидронафтиридины и родственные соединения, подходящие в качестве ингибиторов киназ для лечения пролиферативных заболеваний
JP2008535902A5 (enExample)
JP2017511378A5 (enExample)
JP2019535723A5 (enExample)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2018507257A5 (enExample)
JP2013538213A5 (enExample)
MX2025004221A (es) Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y metodos de uso de los mismos
JP2008508287A5 (enExample)
MX2024002409A (es) Terapias contra el cancer.
WO2016205460A4 (en) Polycyclic derivatives targeting ral gtpases and their therapeutical applications